Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday
Gilead Sciences (NASDAQ:GILD) is set to release its quarterly earnings on February 11, with analysts expecting earnings of $1.66 per share and revenue of $7.15 billion. The company previously reported $2.02 EPS and $7.55 billion revenue, exceeding estimates. Gilead's stock opened at $96.04, with a market cap of $119.69 billion. Recent analyst ratings include upgrades from Morgan Stanley and Sanford C. Bernstein, while insider selling has been noted. The company focuses on biopharmaceuticals, including treatments for HIV/AIDS and COVID-19.
Gilead Sciences (NASDAQ:GILD - Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.66 per share and revenue of $7.15 billion for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Get Gilead Sciences alerts:
- Gilead’s Stock Surge: What’s Fueling the Momentum?
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm's revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 EPS. On average, analysts expect Gilead Sciences to post $4 EPS for the current fiscal year and $8 EPS for the next fiscal year.
Gilead Sciences Stock Performance
Shares of NASDAQ GILD opened at $96.04 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $100.51. The firm has a fifty day moving average price of $93.04 and a 200-day moving average price of $86.65. The stock has a market cap of $119.69 billion, a PE ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.
Analyst Upgrades and Downgrades
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Several equities research analysts have weighed in on GILD shares. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 price objective on the stock. Morgan Stanley upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Maxim Group cut shares of Gilead Sciences from a "buy" rating to a "hold" rating in a report on Friday, November 8th. UBS Group upped their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.39.
View Our Latest Research Report on Gilead Sciences
Insider Buying and Selling
- Positive News is Driving This Cancer Drug Maker’s Stock Higher
In other news, Director Jeffrey Bluestone sold 6,788 shares of the firm's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company's stock.
Gilead Sciences Company Profile
(Get Free Report)Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- The Basics of Support and Resistance
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
- Trading Stocks: RSI and Why it's Useful
- Why New Tariffs Could Boost These 3 Basic Materials Stocks
- What is the S&P/TSX Index?
- MarketBeat Week in Review – 02/03 - 02/07
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Should You Invest $1,000 in Gilead Sciences Right Now?
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
